Genotyping
technologies have advanced the decades-old field of pharmacogenetics whereby drug therapies are designed to be compatible with a patient's specific genetic makeup. Pharmacogenomics combines genetic testing, protein expression analysis, and in vitro drug metabolism to screen patients in advance for responsiveness toward drugs. These technologies may be applied to streamline clinical trials and to target approved drugs to patient populations scored on the basis of their drug metabolism. Where predictive drug testing is successful, results from such studies may be used to determine how drugs can be prescribed for the general population.
One of the core platform technologies of pharmacogenomics is genetic screening and diagnostics for genebased polymorphisms or mutations. The genetic screening and diagnostics technology should reach the level at which it can accurately and consistently detect genetic mutations or polymorphisms before the technology is integrated with proteomics and predictive drug testing. At the very minimum, DNA-based tests should subscribe to current regulations in both the US and Europe, for assay performance standards for diagnostic procedures.
Currently, the US FDA regulates any type of medical testing kit, including genetic testing kits, as a medical device (Medical Device Amendments Act, 21 U.S.C. §360). Genetics-based diagnostics are labeled Class III devices. Before a medical device can be made available to the public, the developers of the device must apply for an Investigational Device Exemption (IDE), which is analogous to the Investigational New Drug Application (IND) required for new drugs. The FDA has maintained that it has the authority to regulate genetic testing laboratories as medical devices, but it has chosen not to do so. The FDA does not regulate small private laboratories, which perform their own genetic test methods. Most genetic testing is done with unregulated reagents that laboratories use to build a testing system. 1 Even assuming, arguendo, that predictive drug testing is considered an aspect of drug research and development, then pharmacogenomics would fall within the realm of preclinical testing, and would remain unregulated under current FDA guidelines for new drug development.
Under the Clinical Laboratory Improvements Act (CLIA), genetic testing falls within the statutory meaning of cytogenetics (42 U.S.C. §263). However, under that classification, CLIA does not require a genetic testing service to be proven proficient. As a whole, CLIA lacks any category devoted to genetic testing much less predictive drug testing on the scale of pharmacogenomics. CLIA imposes requirements on assay performance for accuracy, sensitivity/specificity, reproducibility, reportable ranges of patient results and reference range of assay. Notably, CLIA does not preempt the FDA's authority to regulate a clinical laboratory's devices used in testing. CLIA regulations require laboratories to comply with all applicable federal laws, including FDCA.
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To effectively monitor predictive drug testing, two sets of CLIA assay standards should be considered-one for genomic characterization and genomic testing, and the second for in vitro protein-or cellular-based assays used to detect altered drug metabolizing function.
The CPMP/ICH/137/95 provides guidance on clinical study reports and the contents of the reports as they relate to patients involved in clinical trials, but the guidelines are specifically silent as to preclinical evaluation for drug responsiveness as encompassed by pharmacogenomics.
Molecular assays should be comparable to a single, known standard, which is not cross-reactive with con-taminants. Accuracy, in terms of molecular testing, would be determined by whether an assay has the ability to quantitate equally across different genotypes. Sensitivity at a molecular level means the ability to detect a single copy of a messenger RNA transcript. For the reproducibility of molecular assays it is important that an assay include a multiple-point calibration curve, which is sensitive to the linearity (or the sensitivity of the high and low ranges of results) and dynamic range (or the breadth of the high and low ranges of results). 4 Accuracy, sensitivity and reproducibility are equally important in any methodologies that serve as platform technologies from which other diagnostic procedures are based such as predictive drug testing. In developing genetic test methods, firms should be certified in their testing capabilities for detecting a genotypic variant or a nucleotide polymorphism from any given patient sample. Firms should also be held to a standard, which requires that the data be reproduced in at least three separate experiments. Only after confirmation of the identity of the polymorphism, should a firm be allowed to proceed to the next step of the analysis, which involves proteomics or analysis of protein expression of the genotypic variant.
The identification of a polymorphism in a pharmacologic effect (a) at an early stage in the development of a new drug, (b) in re-evaluating a failed drug candidate or (c) in evaluating patient responsiveness to a marketapproved drug may now be possible through careful pharmacogenomic testing. A predictive drug-testing scheme based on the supposition that there is a genetic polymorphism of drug metabolism might include the following steps: In the matter of the predictive drug testing procedure (steps 1-4, or 9(b)), any firm providing this type of service should guarantee both analytical and clinical validity of the genetic and in vitro tests, which comprise the diagnostic assay. This would include firms linked to medical research institutions but more particularly those that commercialize pharmacogenomic diagnostics to the public sector.
A patient's phenotype for a single given polymorphism, as determined by in vitro methods, may not strictly correlate with that patient's metabolism of a particular targeted drug when administered in vivo. Pharmacogenomic testing neither negates nor reduces responsible drug monitoring for those patients who are later grouped or stratified according to their ability to metabolize a drug in vitro. The patient, consumer, physician and the service provider must be aware that pharmacogenomics yields only predictive and not definitive information on drug metabolizing efficiency in patients prior to treatment.
Another complexity of the system lies in the evaluation of the drug metabolism data. For this step, it is fundamental that the laboratory personnel are familiar with the limitations of various techniques, and that they have the ability to evaluate how test results are going to be used. In either case, the clinician will need test results that can be used to compare a patient's disease status over time. Consequently, this kind of comparative information is problematic where the overall pharmacogenomic test protocol has not met the standards for accuracy or sensitivity. Improperly performed laboratory tests or misinterpretation of predictive drug test data may result in increased health care costs. Still worse, patients who are wrongly classified in their ability to metabolize a drug in vitro may later be subjected to unnecessary and even harmful treatments.
Where a genetic polymorphism has been linked to a drug-metabolizing phenotype for a given patient, the patient should be selected according to their general phenotype for qualifi-cation in a clinical trial (steps 6-8), or the phenotype should be used to assist the prescribing physician in selecting a treatment modality. Those patients exhibiting a severe disability to metabolize a drug in vitro, should be tested preliminarily with the drug before being excluded from any clinical trial or before the prescribing physician elects an alternative means of treatment. A corresponding failure to metabolize the drug in vivo should serve as the definitive indicator that the patient is a poor responder before final disqualification from the study. Other available agents should be used to treat the poorly responding population, or the polymorphism may serve as a substrate on which to base research for new drug designs.
The drug dose response and toxicity ranges determined from preclinical testing, should only serve as approximate concentrations for the treatment regimen in the initial stages of a trial (step 8). Predictive drug testing should not replace careful monitoring of the patient's responsiveness to in vivo administration of the predetermined drug concentration especially where it may be important to modulate the dose within a phenotyped/genotyped patient group.
Under current FDA rules, drug labeling (step 9(a)) is to provide advice on 'known hazards and not theoretical possibilities'. 6, 7 In view of the predictive nature of pharmacogenomics, then those drug manufacturers, who in the future base their drug development programs on pharmacogenomic modeling, would have to subscribe to higher phenotyping and drug testing standards so as not to incur liability for mislabeling of their drug products and the intended patient population. For consumers/patients and physicians alike, consideration should be given to allowing supplementation of the labeling, for purposes of providing information on the correlation between a patient genotype for a gene associated with drug-metabolism in a given disease, and its corresponding phenotype. Labeling should disclose not only risk information on the extrapolation of in vitro pharmacogenomic test results to in vivo drug responsiveness, www.nature.com/tpj but a recommended dosage based on stratified patient groups according to in vitro-based genotype/phenotype profiles.
As genomics-based technologies infiltrate pharmaceutical and clinical laboratory testing settings, the risks of mishandling or misinterpreting data from patient sample analyses becomes a significant consideration with especially dramatic consequences where the tests become commercially available to the public. 8 In the fall of 1997, the Task Force on Genetic Testing released its final recommendations in 'Promoting Safe and Effective Genetic Testing in the US', 9, 10 but no action has ever been taken to adopt this very important proposal. Clearly, in view of the recent explosive growth for this industry the proposed guidelines are now worth reconsideration.
The Task Force guidelines were designed to address genetic testing protocols for offer of service. But the task force report was distinctly void of discussion about predictive drug testing using genomics-based methods. Overlaying predictive drug response testing on genetic testing would add even yet another level of technological complexity to an already complex diagnostic procedure. In addition, it raises several issues concerning the validity of drug response data in view of the complexity of hereditary expression, and the interpretation thereof, by laboratory personnel and physicians.
11 Government-sponsored regulation should reflect consumer's expectations for quality care, but especially where services are commercialized through unregulated independent firms or where test results are not evaluated and approved by qualified physicians. Predictive drug tests without established predictive value are unacceptable for broad commercialization. Such tests are highly subject to misinterpretation by those who undergo them and by the services that market them.
A central premise is that regulatory safeguards must be introduced to ensure that predictive drug testing is made available only when it carries clinically valid, predictive value. Equally important, operators within firms and consumers/patients must be educated about both the technology's limitations and the potential responsiveness of a person to in vivo drug therapy as against predictive in vitro drug testing.
At least within the US, adoption and enforcement of the Task Force recommendations by the FDA, in observance of existing CLIA standards and the FDA drug approval process, would ensure greater proficiency of predictive drug test services, uniformity of assay standards, and most importantly, the promotion of consumer safety. Pharmacogenomics services should not be made available before a total assessment of their benefits and risks.
Pharmacogenomics may be a boon to prescriptive medicine, but the core technologies essential to the design and interpretation of pharmacogenomics-based diagnostics are currently under-regulated by those agencies delegated to do so. More specifically, the clinical and analytical quality of genetic testing and the proficiency and analytical qualifications of predictive drug testing services are either not covered by existing laws and regulations or the coverage is inadequate, given the complexity of technologies underlying pharmacogenomics. Monitoring of drug efficacy on individual patient samples through model systems may even require its own tailored guidelines. Before considering pharmacogenomics a new-age health care medium, the food and drug regulatory agencies should be prepared to take steps to guarantee the quality of testing and the outcome of predictive drug modeling. Oversight of prediction-based drug therapy services on stratified human populations may require an altogether different set of standards, namely that which falls somewhere among a diagnostic (device), a drug therapy and a clinical service. 
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